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ORIGINAL ARTICLE

Percutaneous Venoplasty for Central Venous Stenosis:
Effect on Patient's Symptoms and Patency of Arteriovenous Accesses
Zia Ur Rehman1, Abdul Hakeem1, Raza Sayyani2 and Nida Zahid1
Department of Surgery1 / Radiology2, The Aga Khan University Hospital, Karachi, Pakistan

ABSTRACT
Objective: To determine symptomatic relief and patency rate of arteriovenous (AV) fistulae and grafts after venoplasty in
patients with central venous stenosis (CVS) on hemodialysis.
Study Design: Case series.
Place and Duration of Study: The Aga Khan University Hospital, Karachi, from January 2012 to December 2017.
Methodology: The data of patients who had one session of successful venoplasty for CVS were reviewed. The outcomes
measured were symptomatic recovery and improvement in the patency of AV accesses. Symptomatic recovery was
termed 'complete', when there was complete symptomatic relief after venoplasty; and 'partial' when the procedure was
technically successful, but symptoms were not resolved. Primary patency of AV access was the duration from first
intervention till further intervention. Cumulative patency was the total duration of time fistula remains patent with multiple
interventions. Events, considered end points to functional access status, were placement of new access site, ligation of
access site, dialysis catheter placement or the patient death.
Results: Thirty-five patients had technically successful venoplasty with mean age of 56.86 ±14.6 years. Twenty-one (60%)
were female patients. All patients tolerated the procedure well. Twenty-one (60%) patients had complete relief of
symptoms. Fourteen patients (40%) had partial relief of symptoms. Twenty-one patients required repeat angioplasties. The
mean follow-up was 18.6 ±9.02 months. Primary patency was 40%, 24%, 24% at 6, 12 and 24 months. Cumulative patency
was 69%, 66% and 59% at 6, 12 and 24 months.
Conclusion: Percutaneous venoplasty provided symptomatic relief to the patients and improved the short-term patency
of AV accesses.
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INTRODUCTION
A good functioning AV fistula or graft is directly linked
to improved quality of life of patients on hemodialysis.
Access problems are common and frequent reason of
hospitalisation for these patients.1 The most common
issues of hemodialysis accesses are poor flow, thrombosis, bleeding or inadequate dialysis due to central
venous stenosis (CVS).
About 11% to 40% of the patients on hemodialysis have
CVS.2 Patients with previous history of central line
placement and having AV access on the ipsilateral arm
are at risk of developing CVS.3 Patients may present
with severe arm, neck, and breast oedema.4 They also
have malfunctioning accesses with inadequate dialysis.
Over the last two decades, percutaneous methods have
taken over the surgery for treatment of CVS5 due to their
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minimal invasiveness. They are considered to be
effective in improving the patency of failing AV accesses,6
and also relieving patient's symptoms. There is little
reported in loco-regional literature on the outcomes of
these procedures.7
The objective of this study was to determine the success
of percutaneous venoplasty in terms of relieving symptoms of CVS and improving the patency of AV accesses.

METHODOLOGY
This was a retrospective study conducted at the Aga
Khan University Hospital from January 2012 to December
2017. All patients, who had CVS in upper arm or lower
leg, were included in the study.
Patients who were lost to follow-up or had incomplete
records were excluded from the study. Data about patients’
demographics, symptoms, existing co-morbidities, indication for CVS intervention, and location of lesion were
retrieved and recorded on specially designed proforma.
All patients had standard percutaneous venoplasties
with plain balloons. Technical success was considered when
there was less than 30% residual stenosis. Stenting was
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considered in patients when residual stenosis of more
than 50%, with elastic recoil or with complication.
Patients were monitored for any post-procedure complications such as bleeding, access site hematoma or
access thrombosis. Patients were allowed to use
accesses soon after the procedure, if needed. Patients
were followed in vascular surgery clinics at 3-month
interval.

of the patients was 56.86 ±14.6 years. Most of them
were females (21, 60%). The major comorbidities
were hypertension and diabetes (Table I). Twenty-four
(68.6%) patients had native arteriovenous fistula, while
11 (31.4%) had arteriovenous grafts.

The outcomes measured were symptomatic recovery
and improvement in the patency of arteriovenous access.
Symptomatic recovery was termed 'complete', when
there was complete symptomatic relief after venoplasty;
and 'partial' when the procedure was technically
successful but symptoms that led to venoplasty, were
not resolved.

The most common sites of stenosis were brachiocephalic vein followed by subclavian vein. One patient
had balloon leak, while another patient had cardiac
event in post-procedure day, which settled with medical
management.

Patency of AV accesses were measured as primary and
cumulative patency. Primary patency was the duration of
time from first intervention to next intervention or fistula
failure. Cumulative patency was the total duration of time
fistula remain, patent with multiple interventions.

Twenty-three (65.7%) patients presented with arm swelling,
10 (28.6%) patients with poor flow, and 2 (5.7%) patients
with increased pressure during dialysis.

Twenty-one (60%) patients had initial complete relief
of symptoms and 14 (40%) patients had partial relief.
Primary patency was 40%, 24%, 24% at 6, 12 and 24
months. Cumulative patency was 69%, 66% and 59% at
6, 12 and 24 months (Figures 1 and 2).

Events considered end points to functional access status
were placement of new access site, ligation of access
site, dialysis catheter placement or the patient death.
Categorical variables were reported as frequencies
along with their percentages. Continuous variables were
reported as mean ± standard deviation. Patency rate
was calculated using Kaplan-Meier survival curve. A
p-value of <0.05 was considered as significant. Analyses
were performed using SPSS version 22 (IBM Inc.).

RESULTS
During the study period, 48 patients had attempted
venoplasty. Thirteen patients were excluded as wire was
not negotiable through the lesion. Thirty-five patients
had technically successful venoplasty. The mean age
Table I: Demographics of patients and details of arteriovenous accesses.
N=35

Figure 1: Graph showing primary patency of arteriovenous accesses.

Number (%)

Comorbidities
Hypertension

34 (97.1)

Diabetes mellitus

16 (45.7)

Coronary artery disease

8(22.9)

Hepatitis C

5(14.3)

Polycystic kidney disease

2(5.7)

Hypothyroidism

3(8.6)

Systemic lupus erythrosclerosis

3(8.6)

Site of fistula
Left arm
Right arm

24 (68.6)
9 (25.7)

Left leg

1 (2.9)

Right leg

1 (2.9)

Site of stenosis
Axillary vein

8 (22.9)

Subclavian vein

9 (25.7)

Brachiocephalic vein

16 (45.7)

External Iliac vein

1 (2.9)

Common Iliac vein

1 (2.9)
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Figure 2: Graph showing cumulative patency of arteriovenous accesses.

Journal of the College of Physicians and Surgeons Pakistan 2019, Vol. 29 (12): 1189-1192

Percutaneous venoplasty for central venous stenosis

Twenty-six (74%) patients had recurrence of symptoms.
Twenty-one (60%) patients underwent repeat angioplasty.
Five patients (14%) had surgical management for CVS.
Ligation and formation of new AVF in one patient; two
patients had thrombectomies, while two patients had
bypass procedures for relieving CVS. Four patients had
stents placed. One stent was placed at the time of first
angioplasty and three were placed at the time of the
repeated venoplasty sessions.

DISCUSSION
The present study showed that CVS venoplasty improved
patients’ symptoms and also improved the short term
patency of vascular access. Seventy-four percent
patients had recurrence in which most patients required
repeated venoplasty. There were no major complication
encountered. All accesses were usable for dialysis soon
after the procedure.
Bakken et al. showed improved haemodialysis access
patency of 77%, 73% and 57% at 3, 12 and 24 months
after CVS venoplasty.8 Bountouris et al. also noted
patency of 42% at 24 months.9 Glanz S et al. noted
1-year patency rate of 35%.10 The results are consistent
with this study. Ya et al. showed, PTA for CVC achieved
technical success in 92% of cases, and symptoms were
initially alleviated in 96% of subjects.11 Others have also
documented the efficiency of this modality.12 The authors
also found it effective in relieving patients arm swelling.

CONCLUSION
Percutaneous venoplasty for CVS can provide symptomatic relief in majority of the patients and can improve
the short term patency of arteriovenous access.
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